陈雁如

2017-06-23

本人的科研致力于研究和制作有创新意义的基因编辑技术,在构建高效、经基因修饰的细胞系,动物模型的构建和干细胞研究的领域中有丰富的经验和学术背景。 本人目前担任美国应用干细胞公司Applied StemCell, Inc (ASC)共同创办人、首席科学家、高级副总裁,在加入ASC之前,本人在美国斯坦福大学转基因动物模型中心担任主任一职长达16年之久, 又担任斯坦福大学肿瘤中心副主任7年。 在这段学术生涯中,曾经和很多的科学家和研究人员合作,并帮助他们构建了基因修饰的动物模型,包括转基因和小鼠敲除模型, 共构建1000余只小鼠。 本人近年来的科研致力于开发基因编辑的新技术及在细胞和基因治疗上的应用。 2016年本人及团队投递了6个基因编辑技术的专利, 2017年第一季度又投递了3个基因编辑技术的专利。本人是ASC核心基因整合技术TARGATTTM的发明人之一。 本人所领导的ASC科研队伍在利用基因编辑技术治疗单基因遗传病上已经取得了重大的突破。

Dr. Ruby Yanru Chen-Tsai, PhD, is co-founder of Applied StemCell, where she is currently Chief Scientific Officer.  Dr. Chen-Tsai received her PhD from Cornell University and did her post-doc research at Stanford University. She has been working with stem cells and genetic cell and animal models for 25 years. Prior to joining Applied StemCell, Dr. Chen-Tsai worked at Stanford University for 16 years as Director of the Transgenic Research Center and Associate Director of the Stanford Cancer Institute, where she oversaw nine research technology labs. Dr. Chen-Tsai is a co-inventor of the TARGATT™ integrase technology and a related “DICE” technology for site-specific gene insertion. Her current research focuses on gene and stem cell based therapy using advanced genome editing technologies including CRISPR/Cas9 and Applied StemCell’s proprietary TARGATTTM technologies. Dr. Chen-Tsai has authored manuscripts in top tier journals, such as Science, PNAS, and Cell Stem Cell, and holds multiple patents. She has been awarded grants from the NIH, the California Institute of Regenerative Medicine, and Invest Northern Ireland.

上一篇:吴力军
下一篇:孙磊
Powered by 飞色网络